Seeking Alpha

chongkim74

chongkim74
Send Message
View as an RSS Feed
View chongkim74's Comments BY TICKER:
Latest  |  Highest rated
  • Rite Aid higher after Credit Suisse chimes in on M&A potential [View news story]
    I really think WBA is the best suitor for RAD…maybe this is why they consolidated 200 stores…hmm. LONG RAD. Maybe a tiny miss or break even with earnings but guidance forecast should be very positive.
    Jun 17, 2015. 12:03 PM | Likes Like |Link to Comment
  • Rite Aid: What To Expect When It Reports Earnings On Thursday [View article]
    RITE AID: WHAT ARE THE EXPERTS SAYING AHEAD OF EARNINGS?Font size: A | A | A
    undefined undefined | S&P Capital IQ
    SNPMarketScopeViewsNew... 16:39:22.000RADRITE AID CORPORATIONAcquire MediaRITE AID: WHAT ARE THE EXPERTS SAYING AHEAD OF EARNINGS? Shares of Rite Aid Corporation (NYSE: RAD) have surged more than 17.6 percent in the past three months, as the stock has recently made a push make new all-time highs. With the company set to release earnings on Thursday, is now the time for traders to be taking profits in the drug store, or is the sky the limit for Rite Aid's stock? In the past couple of weeks, several top Wall Street firms have weighed in on Rite Aid. Here's a summary of what they believe is in store for investors. UBS analysts believe that the foundation is in place for Rite Aid to exceed Wall Street earnings consensus "by a fairly wide amount." UBS has a Buy rating on Rite Aid and a $10 target for the stock. Credit Suisse analysts believe that Rite aid "provides one of the more compelling risk/reward profiles in our space." The firm has an Outperform rating on Rite Aid and a $10 target for the stock. Related Link: Oracle, Rite Aid And Fedex Highlight Quiet Earnings Week Deutsche Bank analysts see "multiple drivers for EPS growth" at Rite Aid, including the acquisition of Envision. Deutsche Bank has a Buy rating on Rite Aid and a $10 target for the stock. Analysts at Evercore like the "generally positive underlying fundamentals" at Rite Aid. Evercore has a Buy rating on the stock and a $9.50 target set. Despite soft sales estimates for the quarter, Cowen analysts "continue to believe guidance may prove conservative as we see upside from generic introductions, the new Wellness+ Plenty program, reimbursement pressure assumptions and the potentially early closing of Envision Rx." Cowen has an Outperform rating on Rite Aid and a $12 target for the stock. Image Credit: Public Domain View More Analyst Ratings for RADView the Latest Analyst Ratings Write to editorial@benzinga.com with any questions about this content. Subscribe to Benzinga PRO: http://pro.benzinga.com 2015 Benzinga Newswires. Benzinga does not provide investment advice. All rights reserved. Acquire Media|US;RAD|41603|US|...
    Jun 17, 2015. 11:59 AM | Likes Like |Link to Comment
  • Rite Aid: What To Expect When It Reports Earnings On Thursday [View article]
    Sorry TGT will give up the OTC goods found in CVS stores to CVS with the deal. They are completely out from the drug store biz, in return for a handsome capital and influx of new customers. This was a nice move from both parties.
    Jun 16, 2015. 05:10 PM | 1 Like Like |Link to Comment
  • Don't Over Think This: Wal-Mart Is A Buy [View article]
    So can anybody explain why WMT fell down so hard?? I haven't found a good reason why it fell so hard besides strong dollar. Thanks
    Jun 15, 2015. 05:38 PM | 1 Like Like |Link to Comment
  • Rite Aid: What To Expect When It Reports Earnings On Thursday [View article]
    TGT+CVS=new market share for CVS. They will lose significantly on OTC sales, but they feel just prescriptions alone will generate enough new markets from TGT.
    Your article was interesting. Thanks for sharing your thoughts and data. I like RAD. It should break their highs and head to new grounds nice and easy...
    Jun 15, 2015. 04:46 PM | 1 Like Like |Link to Comment
  • Liquidmetal begins knife deliveries from manufacturing facility [View news story]
    Anybody know how much gross revenue or net profit or how much orders were placed?
    Jun 12, 2015. 09:29 AM | 1 Like Like |Link to Comment
  • Galena up on ASCO abstracts on NeuVax and GALE-301 [View news story]
    Never mind. Thanks.
    Jun 12, 2015. 09:06 AM | Likes Like |Link to Comment
  • Yahoo -2.5%; Capstone calls IRS Alibaba spinoff approval unlikely [View news story]
    Analysts from CNBC and others stated that even with the IRS tax baked in the value of Yahoo is around 44$ to $45.
    Jun 11, 2015. 05:12 PM | 3 Likes Like |Link to Comment
  • Yahoo -2.5%; Capstone calls IRS Alibaba spinoff approval unlikely [View news story]
    RIGHT…IRS agent who was not qualified to officially talk about changing regulations for IRS spoke at a luncheon about it. Give me a break. IRS will announce it officially when it happens and I disagree with Capstone..Spinoff submission was in before IRS said they won't accept anymore until its decided…gosh, who's Capstone anyways.
    Jun 11, 2015. 05:10 PM | 3 Likes Like |Link to Comment
  • Galena up on ASCO abstracts on NeuVax and GALE-301 [View news story]
    Yes, inquirers want to know!!
    Jun 11, 2015. 04:58 PM | 1 Like Like |Link to Comment
  • Yahoo's Alibaba Failure [View article]
    HOLD.
    Jun 11, 2015. 04:57 PM | Likes Like |Link to Comment
  • Galena up on ASCO abstracts on NeuVax and GALE-301 [View news story]
    John,

    I totally agree with you…and it seems to agree with me..that 2.00$ is the resistance we are facing due to the shorts. You agree this is a hold. I don't recommend buying more with low volume and publicly available data and records for this company, this stock is not soaring..I think the price is baked in for now…unless the heavy hitters grab pallets and pallets of these…we will be testing the resistance for a while. Btw…I have been on this stock for over 2 years…sold before it totally bombed on us 2104 winter..and I felt terrible for people who still held it since then…listening to euphoric commenters here saying hold hold hold or buy buy during winter 2014 while themselves sold…I say HOLD for holders and have caution for new buyers…why? Cuz with the all the positive data we have, this stock can't beat the resistance..something is not that positive then. Ive witnessed and made $ in 2014 winter when it went up to $7 and dropped in a blink of an eye..Be well…
    Jun 11, 2015. 04:00 PM | 1 Like Like |Link to Comment
  • Rite Aid higher after Credit Suisse chimes in on M&A potential [View news story]
    In a report published Thursday, Credit Suisse analyst Edward J. Kelly reinstated coverage of Rite Aid Corporation
    RAD 2.55%
    with an Outperform rating and a price target of $10. The analyst believes that the stock offers a compelling risk/reward profile.

    "The company has made good progress on its turnaround and we expect further improvement as management pushes forward with numerous, traffic-focused initiatives. The recent acquisition of EnvisionRx only enhances the company's outlook," the Credit Suisse report said.

    Apart from the positive fundamental outlook, the stock also has another "realistic" avenue for upside through M&A. The analyst believes that the industry is poised for further consolidation and Rite Aid is likely to be an attractive acquisition target.

    The company has been able to increase its EBITDA over 50 percent over the last four years, driven by industry tailwinds, missteps by competitors and improvements in internal execution. The analyst believes that Rite Aid might be able to sustain average organic EBITDA growth in the mid single digit range over the next few years.

    "We expect RAD's turnaround to continue at a steady pace, as its remodel initiative (only 36 percent complete), the new generic procurement deal with MCK, further loyalty/wellness enhancements, and another round of generic launches more than offset sustained reimbursement rate pressure," Kelly stated.

    In addition, the analyst believes that being acquired would make strategic sense for Rite Aid currently, since a deal would help add significant scale at retail, enabling the company to better manage reimbursement rate pressure, and would unlock significant cost synergies. The deal also offers considerable revenue synergies given the performance gap between the two players," Kelly added.

    Latest Ratings for RAD

    Date Firm Action From To
    Jun 2015 Credit Suisse Reinstates Outperform
    Jun 2015 Credit Suisse Reinstates Outperform
    May 2015 Mizuho Securities Initiates Coverage on Buy


    Read more: http://bit.ly/1FLuvMs
    Jun 11, 2015. 09:44 AM | 4 Likes Like |Link to Comment
  • Rite Aid higher after Credit Suisse chimes in on M&A potential [View news story]
    Anybody find more detail about how SUISSE talks about potential M&A? Thanks.
    Jun 11, 2015. 09:42 AM | Likes Like |Link to Comment
  • Galena up on ASCO abstracts on NeuVax and GALE-301 [View news story]
    Not that I don't like Gale…but here in SA everyone seems to be doing it for themselves…any negative or sublime comments and you get hanged. Anybody remember how fast Gale fell down couple of summers ago?? Again, I like their results, the dream team seems to be gone, but I see the resistance with Gale right now..so I said HOLD..so burn me to the stake…cuz you guys want to hear only ONE POINT of view here…and thats UP UP UP. I wish that happened…
    So I will HOLD on to my shares and see the movement to break this resistance..gl,all.
    Jun 11, 2015. 09:39 AM | Likes Like |Link to Comment
COMMENTS STATS
1,318 Comments
754 Likes